MET 14 Deletion in Sarcomatoid Non-Small-Cell Lung Cancer Detected by Next-Generation Sequencing and Successfully Treated with a MET Inhibitor

Journal of Thoracic Oncology

Volumn 10, Issue 12, 2015, Pages e113-e114

  Lee, Carrie ^a   Usenko, Dimitry ^a   Frampton, Garrett M ^b   McMahon, Caitlin ^b   Ali, Siraj M ^c   Weiss, Jared ^a  

^a UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

^b Clinical Bioinformatics Operations   (United States)

^c FOUNDATION MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CRIZOTINIB; CYTOKERATIN 7; PACLITAXEL; SCATTER FACTOR RECEPTOR; VIMENTIN; MET PROTEIN, HUMAN;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DRUG RESPONSE; GENE DELETION; HUMAN; MALE; MIDDLE AGED; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; NOTE; POINT MUTATION; PRIORITY JOURNAL; GENETICS; HIGH THROUGHPUT SEQUENCING; LUNG TUMOR;

CARCINOMA, NON-SMALL-CELL LUNG; GENE DELETION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MET;

EID: 84947942831     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000645     Document Type: Article

References (5)

1. Frampton GM, Ali SM, Rosenzweig M, et al. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 2015;8: 850-859.
2. Jenkins RW, Oxnard GR, Elkin S, Sullivan EK, Carter JL, Barbie DA. Response to crizotinib in a patient with lung adenocarcinoma harboring a MET splice site mutation. Clin Lung Cancer 2015 [Epub ahead of print].
3. Paik PK, Drilon A, Fan PD, et al. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov 2015;5:842-849.
4. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012;489:519-25.
5. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014;511: 543-50.